245 related articles for article (PubMed ID: 28094841)
21. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan R; Garcia JS; Percival ME; Berube C; Coutre S; Gotlib J; Greenberg P; Liedtke M; Hewitt R; Regan K; Williamson C; Doykan C; Cardone MH; McMillan A; Medeiros BC
Leuk Lymphoma; 2016; 57(3):609-15. PubMed ID: 26374199
[TBL] [Abstract][Full Text] [Related]
22. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
Xicoy B; Jiménez MJ; García O; Bargay J; Martínez-Robles V; Brunet S; Arilla MJ; Pérez de Oteyza J; Andreu R; Casaño FJ; Cervero CJ; Bailén A; Díez M; González B; Vicente AI; Pedro C; Bernal T; Luño E; Cedena MT; Palomera L; Simiele A; Calvo JM; Marco V; Gómez E; Gómez M; Gallardo D; Muñoz J; de Paz R; Grau J; Ribera JM; Benlloch LE; Sanz G
Leuk Lymphoma; 2014 Jun; 55(6):1300-3. PubMed ID: 23952246
[TBL] [Abstract][Full Text] [Related]
23. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.
Garcia-Manero G; Santini V; Almeida A; Platzbecker U; Jonasova A; Silverman LR; Falantes J; Reda G; Buccisano F; Fenaux P; Buckstein R; Diez Campelo M; Larsen S; Valcarcel D; Vyas P; Giai V; Olíva EN; Shortt J; Niederwieser D; Mittelman M; Fianchi L; La Torre I; Zhong J; Laille E; Lopes de Menezes D; Skikne B; Beach CL; Giagounidis A
J Clin Oncol; 2021 May; 39(13):1426-1436. PubMed ID: 33764805
[TBL] [Abstract][Full Text] [Related]
24. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Katterling RP; Tallman MS; Gore SD
Br J Haematol; 2014 Oct; 167(1):62-8. PubMed ID: 24995683
[TBL] [Abstract][Full Text] [Related]
25. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
26. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.
Bernal T; Martínez-Camblor P; Sánchez-García J; de Paz R; Luño E; Nomdedeu B; Ardanaz MT; Pedro C; Amigo ML; Xicoy B; del Cañizo C; Tormo M; Bargay J; Valcárcel D; Brunet S; Benlloch L; Sanz G; ; ;
Leukemia; 2015 Sep; 29(9):1875-81. PubMed ID: 25943181
[TBL] [Abstract][Full Text] [Related]
28. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Garcia-Manero G; Jabbour E; Borthakur G; Faderl S; Estrov Z; Yang H; Maddipoti S; Godley LA; Gabrail N; Berdeja JG; Nadeem A; Kassalow L; Kantarjian H
J Clin Oncol; 2013 Jul; 31(20):2548-53. PubMed ID: 23733767
[TBL] [Abstract][Full Text] [Related]
29. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure.
Duong VH; Lin K; Reljic T; Kumar A; Al Ali NH; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):711-5. PubMed ID: 24054159
[TBL] [Abstract][Full Text] [Related]
30. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Kantarjian HM; O'Brien S; Huang X; Garcia-Manero G; Ravandi F; Cortes J; Shan J; Davisson J; Bueso-Ramos CE; Issa JP
Cancer; 2007 Mar; 109(6):1133-7. PubMed ID: 17315156
[TBL] [Abstract][Full Text] [Related]
31. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
Dickinson M; Cherif H; Fenaux P; Mittelman M; Verma A; Portella MSO; Burgess P; Ramos PM; Choi J; Platzbecker U;
Blood; 2018 Dec; 132(25):2629-2638. PubMed ID: 30305280
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P; Mufti GJ; Hellstrom-Lindberg E; Santini V; Finelli C; Giagounidis A; Schoch R; Gattermann N; Sanz G; List A; Gore SD; Seymour JF; Bennett JM; Byrd J; Backstrom J; Zimmerman L; McKenzie D; Beach C; Silverman LR;
Lancet Oncol; 2009 Mar; 10(3):223-32. PubMed ID: 19230772
[TBL] [Abstract][Full Text] [Related]
33. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Thépot S; Ben Abdelali R; Chevret S; Renneville A; Beyne-Rauzy O; Prébet T; Park S; Stamatoullas A; Guerci-Bresler A; Cheze S; Tertian G; Choufi B; Legros L; Bastié JN; Delaunay J; Chaury MP; Sanhes L; Wattel E; Dreyfus F; Vey N; Chermat F; Preudhomme C; Fenaux P; Gardin C;
Haematologica; 2016 Aug; 101(8):918-25. PubMed ID: 27229713
[TBL] [Abstract][Full Text] [Related]
35. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Thepot S; Itzykson R; Seegers V; Raffoux E; Quesnel B; Chait Y; Sorin L; Dreyfus F; Cluzeau T; Delaunay J; Sanhes L; Eclache V; Dartigeas C; Turlure P; Harel S; Salanoubat C; Kiladjian JJ; Fenaux P; Adès L;
Blood; 2010 Nov; 116(19):3735-42. PubMed ID: 20664061
[TBL] [Abstract][Full Text] [Related]
36. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
[TBL] [Abstract][Full Text] [Related]
37. Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
Garcia-Manero G; Kazmierczak M; Wierzbowska A; Fong CY; Keng MK; Ballinari G; Scarci F; Adès L
Leuk Res; 2024 May; 140():107480. PubMed ID: 38499457
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
39. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Sallman DA; Al Malki MM; Asch AS; Wang ES; Jurcic JG; Bradley TJ; Flinn IW; Pollyea DA; Kambhampati S; Tanaka TN; Zeidner JF; Garcia-Manero G; Jeyakumar D; Komrokji R; Lancet J; Kantarjian HM; Gu L; Zhang Y; Tan A; Chao M; O'Hear C; Ramsingh G; Lal I; Vyas P; Daver NG
J Clin Oncol; 2023 May; 41(15):2815-2826. PubMed ID: 36888930
[TBL] [Abstract][Full Text] [Related]
40. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
